Piramal Pharma Limited completed the acquisition of a controlling stake in Yapan Bio Private Limited on Wednesday [4].
The move strengthens Piramal Pharma's footprint in the biologics sector, expanding its capacity to manufacture vaccines and other complex biological products.
Based in Hyderabad, India, Yapan Bio operates as a contract development and manufacturing organization. Piramal Pharma acquired an incremental stake of 40.67% [1] to secure a majority position in the company.
Following the transaction, Piramal Pharma's total shareholding in Yapan Bio has reached 74% [2]. The company paid a cash consideration of ₹76 crore [3] to finalize the deal.
The acquisition brings Yapan Bio under the subsidiary structure of Piramal Pharma. This integration is designed to scale the parent company's vaccine manufacturing capabilities and enhance its overall biologics portfolio [5].
Industry analysts said the Hyderabad location is a primary hub for pharmaceutical innovation in India. By controlling Yapan Bio, Piramal Pharma gains direct oversight of specialized manufacturing processes required for biological drugs, a sector that requires more stringent controls than traditional chemical drug synthesis.
The completion of the deal on Aug. 19 marks the final step in the transition of Yapan Bio into the Piramal corporate umbrella [4].
“Piramal Pharma's total shareholding in Yapan Bio has reached 74%”
This acquisition signals a strategic pivot toward high-growth biologics and vaccine production. By securing a 74% majority stake in a specialized CDMO, Piramal Pharma reduces its reliance on third-party manufacturers and integrates critical technical expertise into its own supply chain, positioning itself to compete more aggressively in the global biologics market.
